ClinicalTrials.gg
CompletedNCT07285317Updated Dec 16, 2025

Safety and Tolerability Evaluationof Phascolarcobacterium Faecium

A Phase 1 interventional study of Bacterium P. faecium in Health, Obesity Type 2 Diabetes Mellitus and Obesity & Overweight, sponsored by Spanish National Research Council. Completed at 1 site in Spain. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by Spanish National Research Council · Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Feb 2024, registered Nov 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 390 studies in Obesity with a site in Spain — 95 open to participants now, 134 under way, 45 of them phase 3. Obesity · Spain.

Enrollment
319th of 332
20 · median 124
Started
2024
with 31 others
Phase 1
4 of 390
2 open now
Registered
332nd of 390
by date

Among the 390 studies in Obesity with a site in Spain, this one is the 319th largest by enrollment of the 332 interventional ones that give a count, is one of 32 that started in 2024, is one of 4 in phase 1, and was the 332nd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

95 of the 390 studies in Obesity with a site in Spain are open now. Recruiting first, the newest first:

90 more — sign in →

All 95 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 390 studies in Obesity with a site in Spain, or all of them as a file.
02

Study summary

The goal of this interventional study is to assess the safety and tolerability of the daily administratrion of bacterium Phascolarctobacterium faecium in healthy adults with normal weight, and in individuals with overweight and alterations in glucose metabolism. The main questions this study aims to answer are:

Is the bacterium intake safe? Is the bacterium intake well tolerated? The objecitves are to assess if the intake of the bacterium is well tolerated by assessing gastrointenstinal symptoms, and safe, by assessing biochemical markers, incidence of adverse events and the general health status.

Participants will take daily the bacterium for 15 days. Study assessments include stool collection for microbiota analysis; blood sampling form biochemical tests, anthropometric measurements, and validated questionnaires on diet, physical activity, and perceived health.

Read the detailed description

A total of 20 adult volunteers will consume a daily dose of Phascolarctobacterium faecium once per day for 15 consecutive days. Stool and blood samples will be collected at baseline and after the intervention; blood draws will be performed following an overnight fasting of at least 8 hours. Participants will also complete online questionnaires assessing sociodemographic characteristics, gastrointestinal symptoms, bowel habits, general health status, physical activity, and dietary habits. In addition, body composition parameters will be evaluated.

03

Conditions studied

  • Health
  • Obesity Type 2 Diabetes Mellitus
  • Obesity & Overweight

Keywords

  • Gut microbiota
  • Obesity
  • Metabolic health
  • Probiotic
  • Phascolarctobacterium faecium
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-65 years
  • stable body weight and dietary habits during the previous three months
  • written

Exclusion criteria

Exclusion Criteria:

  • the presence of gastrointestinal disorders
  • immunodeficiency
  • eating disorders
  • antibiotic use within one month before the study
  • chronic antidiabetic therapy
  • substance (drug) abuse
  • restrictive diets
  • any other condition deemed inappropriate for participation by the clinician
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    P. faecium in healthy normal weight individuals

    Healthy normal weight individuals will receive a daily dose of P. faecium for 15 days to evaluate the tolerability and safety of short-term administration.

    Dietary Supplement: Bacterium P. faecium

  • Experimental
    P. faecium in overweight individuals with mild alterations in glucose homeostasis

    Overweight individuals with mild alterations in glucose homeostasis will receive P. faecium for 15 days to evaluate its safety and tolerability in the target population.

    Dietary Supplement: Bacterium P. faecium

Interventions

  • Dietary supplementBacterium P. faecium

    The participants will be given Phascolarctobacterium faecium orally (pill form) for 15 consecutive days.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events and general health status

    Participants will have access to a 24-hour contact number to report any inconvenience or adverse effects. All adverse effects will be recorded throughout the intervention period and for one additional week after completion. Outcomes will be reported as the presence or absence of adverse effects.

    Time frame: 21 days

  2. Systemic safety of P. faecium intake assessed in all the clinical trial participants by biochemical markers

    Complete hemogram and biochemical analysis will be permormed at baseline and after bacterum intervention and includes red blood cells, white blood cells, and assessments of lipid profile (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol, and non-HDL cholesterol), renal function (urea, creatinine, and uric acid), hepatic function (total protein, AST, and ALT), and glucose homeostasis (glucose, insulin, HbA1c, and HOMA-IR). All parameters will be measured using standard units commonly applied in clinical practice, and results will be compared before and after the intervention. It will be interpreted as either unchanged or altered relative to baseline values.

    Time frame: 15 days

  3. Tolerability assessment measured by stool habit

    To assess the tolerability of P. faecium, participants will complete gastrointestinal symptom questionnaires before and after the intervention, capturing both weekly bowel movement frequency and stool consistency using the Bristol Stool Scale. Stool habits will be evaluated by integrating these two variables: a normal habit will be defined as 4-14 bowel movements per week together with a Bristol score of 3-5, whereas any deviation from these ranges will be classified as an altered stool habit.

    Time frame: 15 days

  4. Tolerability assessment measured by the frequency of heartburn.

    Use of probiotic bacteria may occasionally elicit mild gastrointestinal discomfort, including bloating, gas or abdominal cramps. To assess the tolerability of the tested bacterium, participants will complete gastrointestinal symptom questionnaires before and after the intervention, which also capture the frequency of heartburn. Response options include: "all the time," "most of the time," "sometimes," "a few times," and "never." Changes in frequency will be compared between pre- and post-treatment assessments.

    Time frame: 15 days

  5. Tolerability assessment measured by the frequency of abdominal bloating.

    Use of probiotic bacteria may occasionally elicit mild gastrointestinal discomfort, including bloating, gas or abdominal cramps. To assess the tolerability of the tested bacterium, participants will complete gastrointestinal symptom questionnaires before and after the intervention, which also capture the frequency of abdominal bloating. Response options include: "all the time," "most of the time," "sometimes," "a few times," and "never." Changes in frequency will be compared between pre- and post-treatment assessments.

    Time frame: 15 days

  6. Tolerability assessment measured by the frequency of constipation.

    Use of probiotic bacteria may occasionally elicit mild gastrointestinal discomfort, including bloating, gas or abdominal cramps. To assess the tolerability of the tested bacterium, participants will complete gastrointestinal symptom questionnaires before and after the intervention, which also capture the frequency of constipation. Response options include: "all the time," "most of the time," "sometimes," "a few times," and "never." Changes in frequency will be compared between pre- and post-treatment assessments.

    Time frame: 15 days

  7. Tolerability assessment measured by the frequency of diarrhea.

    Use of probiotic bacteria may occasionally elicit mild gastrointestinal discomfort, including bloating, gas or abdominal cramps. To assess the tolerability of the tested bacterium, participants will complete gastrointestinal symptom questionnaires before and after the intervention, which also capture the frequency of diarrhea. Response options include: "all the time," "most of the time," "sometimes," "a few times," and "never." Changes in frequency will be compared between pre- and post-treatment assessments.

    Time frame: 15 days

  8. Tolerability assessment measured by the frequency of nausea.

    Use of probiotic bacteria may occasionally elicit mild gastrointestinal discomfort, including bloating, gas or abdominal cramps. To assess the tolerability of the tested bacterium, participants will complete gastrointestinal symptom questionnaires before and after the intervention, which also capture the frequency of nausea. Response options include: "all the time," "most of the time," "sometimes," "a few times," and "never." Changes in frequency will be compared between pre- and post-treatment assessments.

    Time frame: 15 days

  9. Tolerability assessment measured by the frequency of flatulence.

    Use of probiotic bacteria may occasionally elicit mild gastrointestinal discomfort, including bloating, gas or abdominal cramps. To assess the tolerability of the tested bacterium, participants will complete gastrointestinal symptom questionnaires before and after the intervention, which also capture the frequency of flatulence. Response options include: "all the time," "most of the time," "sometimes," "a few times," and "never." Changes in frequency will be compared between pre- and post-treatment assessments.

    Time frame: 15 days

07

Study locations

1 site
  • Instituto de Agroquímica y Tecnología de Alimentos (IATA-CSIC)
    Valencia, Spain
08

References and documents

Publications

  • Liebana-Garcia R, Lopez-Almela I, Olivares M, Romani-Perez M, Manghi P, Torres-Mayo A, Tolosa-Enguis V, Flor-Duro A, Bullich-Vilarrubias C, Rubio T, Rossini V, Segata N, Sanz Y. Gut commensal Phascolarctobacterium faecium retunes innate immunity to mitigate obesity and metabolic disease in mice. Nat Microbiol. 2025 Jun;10(6):1310-1322. doi: 10.1038/s41564-025-01989-7. Epub 2025 May 6. PubMed 40328980 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Jan 2025, 11 months.

Of 105 non-industry phase 1 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 57. This study's 11 months is below that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Dec 16, 2025
StartActual
Feb 1, 2024
Primary completionActual
Jan 30, 2025
CompletionActual
Jan 31, 2025
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07285317
Lead sponsor
Spanish National Research Council
Responsible party
Yolanda Sanz Herranz (Professor, Spanish National Research Council) — Principal investigator
First posted
Dec 16, 2025
Start date
Feb 1, 2024
Primary completion
Jan 30, 2025
Completion
Jan 31, 2025
Last update
Dec 16, 2025

Study contacts

Yolanda Sanz, Professor
principal investigator · Instituto de Agroquímica y Tecnología de Alimentos (IATA-CSIC)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion